Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

By afschroeder • March 8, 2026

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. Breast Cancer Res Treat. 2026 Mar 7;216(2):22. doi: 10.1007/s10549-026-07935-3. PMID: 41793559; PMCID: PMC12967648.

Tags: Cyclin-dependent kinase 4/6, Hematology/Oncology, metastatic breast cancer, overall survival, Publications, real-world data, Target trial emulation

Related Posts

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study

LeVee A, Santos B, Wong M, Ruel N, Schmolze D, Kang I, Tsai K, Mortimer J, McArthur H. Predictors of pathologic complete response in early-stage[...]

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

Piotrowska Z, Goldberg SB, Goldman JW, de Langen AJ, Le X, Okamoto I, Riess JW, Yu HA, Nishino K, Novello S, Ponce S, Ambrose H,[...]

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]